Adjunctive Statin Therapy on Cholesterol and Clinical Symptoms in Schizophrenia Treated with Risperidone

Irma Santy (Department of Psychiatry, Faculty of Medicine, University of Hasanuddin, Makassar, Indonesia)
Andi Ummulkhair Pawallangi Irawan (Psychiatry Specialist Program, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia)
Erlyn Limoa (Department Psychiatry, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia)
Fanny Wijaya (Department Psychiatry, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia)
Ilma Khaerina Amaliyah Bakhtiar (Department of Psychiatry, Faculty of Medicine, Universitas Muslim Indonesia, Makassar, Indonesia)
Muhammad Alim Jaya (Department of Psychiatry, Faculty of Medicine, Universitas Muslim Indonesia, Makassar, Indonesia)

UMI Medical Journal
Vol 10 No 2 (2025): UMI Medical Journal

Background: Schizophrenia is associated with the metabolic side effects of atypical antipsychotics, such as hypercholesterolemia. Objective: To evaluate the effect of adjuvant statin therapy on total cholesterol levels and clinical symptoms in patients with schizophrenia treated with risperidone. Methods: This randomized clinical trial was conducted on 36 patients with schizophrenia at RSKD Dadi, South Sulawesi. The subjects were randomized into risperidone-only and risperidone plus statin groups. Results: Statin adjuvant therapy reduced total cholesterol levels and improved clinical symptoms (PANSS scores) compared to the control group. Conclusion: Adjuvant statin therapy is potentially beneficial in reducing cholesterol levels and improving clinical outcomes in patients with schizophrenia receiving risperidone.